Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory randomized trial of JTR-161 in acute ischemic stroke
jRCT1080224505Phase 2Completed
- Sponsor
- Teijin Pharma
- Start
- Jan 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JTR-161 in brain infarction (3 arms), sponsored by Teijin Pharma. Primary endpoint: Excellent functional outcome at Day 91. Started Jan 2019; status: completed.
02
Drugs
JTR-161
03
Conditions
brain infarction
Beyond the preview
Go deeper on jRCT1080224505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224505.